(Q43031802)

English

Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance

scientific article published in May 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

author name string

Katayama K

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Kasahara A

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sasaki Y

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Kashiwagi T

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Naito M

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Masuzawa M

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Katoh M

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yoshihara H

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Kamada T

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Mukuda T

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hijioka T

11

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hori M

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hayashi N

13

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 May 2001

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

180-185

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00274.X

21 January 2018

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00274.X

21 January 2018

Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00274.X

21 January 2018

Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00274.X

21 January 2018

Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00274.X

21 January 2018

High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00274.X

21 January 2018

Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00274.X

21 January 2018

High levels of serum interleukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00274.X

21 January 2018

Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00274.X

21 January 2018

Interleukin 10 production correlates with pathology in human Leishmania donovani infections

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00274.X

21 January 2018

Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00274.X

21 January 2018

Interferon gamma inhibits interleukin 10 production by monocytes

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00274.X

21 January 2018

Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00274.X

21 January 2018

Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00274.X

21 January 2018

Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00274.X

21 January 2018

Factors predictive of a beneficial response to therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00274.X

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00274.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00274.X

21 January 2018

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00274.X

21 January 2018

Identifiers

10.1046/J.1365-2893.2001.00274.X

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43031802&oldid=2038897000"